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Background: In osteoarthritis (OA) treatment, although chondroitin sulfate (CS) was found in a number of studies
using radiography to have a structure-modifying effect, to date CS use is still under debate. A clinical study using
quantitative magnetic resonance imaging (qMRI) is therefore of the utmost importance. Here we report data from
a 24-month, randomised, double-blind, double-dummy, controlled, comparative exploratory study of knee OA.
The primary endpoint was to determine the effect of CS 1200 mg/day versus celecoxib 200 mg/day on cartilage
volume loss (CVL) in the lateral compartment over time as measured by qMRI. Secondary endpoints included
assessment of the OA structural changes and signs and symptoms of OA.
Methods: qMRI was performed at baseline and at 12 and 24 months. CVL, bone marrow lesion size, and synovial
thickness were evaluated using qMRI. The primary statistical analysis was carried out on the modified intention-to-treat
(mITT) population (n = 138) using chi-squared, Fisher’s exact, Wilcoxon Mann–Whitney, and Student’s t tests and
analysis of covariance. Analyses were also conducted on the according-to-protocol (ATP; n = 120) population.
Results: In the adjusted mITT analysis, compared with celecoxib treatment, patients treated with CS had a
significant reduced CVL at 24 months in the medial compartment (celecoxib –8.1 % ± 4.2, CS –6.3 % ± 3.2; p = 0.018)
and medial condyle (–7.7 % ± 4.7, –5.5 % ± 3.9; p = 0.008); no significant effect was seen in the lateral compartment. In
the ATP population, CS reduced CVL in the medial compartment at 12 months (celecoxib –5.6 % ± 3.0, CS –4.5 % ± 2.6;
p = 0.049) and 24 months (celecoxib –8.4 % ± 4.2, CS –6.6 % ± 3.3; p = 0.021), and in the medial condyle at 24 months
(celocoxib –8.1 % ± 4.7, CS –5.7 % ± 4.0; p = 0.010). A trend towards a statistically reduced synovial thickness
(celecoxib +17.96 ± 33.73 mm, CS –0.66 ± 22.72 mm; p = 0.076) in the medial suprapatellar bursa was observed in
CS patients. Both groups experienced a marked reduction in the incidence of patients with joint swelling/effusion
and in symptoms over time. Data showed similar good safety profiles including cardiovascular adverse events for
both drugs.
Conclusion: This study demonstrated, for the first time in a 2-year randomised controlled trial using qMRI, the
superiority of CS over celecoxib at reducing CVL in knee OA patients.
Trial registration: ClinicalTrials.gov NCT01354145. Registered 13 May 2011.
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Knee osteoarthritis (OA) is one of the most common
musculoskeletal disorders, which causes joint pain,
stiffness, and loss of function [1, 2]. Current treatment
recommendations include a combination of non-
pharmacological (e.g. education, exercise, weight loss)
and pharmacological (e.g. acetaminophen, non-steroidal
anti-inflammatory drugs (NSAIDs)) treatments, and
some also suggest the use of symptomatic slow-acting
drugs for osteoarthritis (SYSADOA) [3–5], which in-
clude chondroitin sulfate (CS) and glucosamine. However,
the use of the latest line of treatment has not reached a
general consensus among different guidelines [6, 7],
due in part to the unavailability of prescription quality
SYSADOAs indicated for use in OA that have been
evaluated by the US Food and Drug Administration [6].
The goals of OA therapy are to decrease pain and
maintain or improve joint function. Existing pharmaco-
logic therapies for OA, namely NSAIDs and analgesics,
help to reduce symptoms, but are only moderately
effective and expose patients to potential significant
toxicity (cardiovascular, hepatic, renal, and other adverse
events (AEs)) and problems resulting from interactions
with other medications. A recent systematic literature
review suggests that paracetamol, especially at the upper
end of standard analgesic doses, can also induce gastro-
intestinal events (i.e. gastroduodenal ulcers and compli-
cations such as upper gastrointestinal haemorrhages)
and renal events (decrease in glomerular filtration rate)
[8]. For this reason, attention has recently been focused
on the investigation and development of new types of
drugs and treatments that can improve the clinical
symptoms of OA and show better safety profiles, such as
symptomatic SYSADOAs. SYSADOAs such as CS are
characterised by a slow onset of action and a global
efficacy at reducing OA symptoms similar to that of
NSAIDs, and also possess a carry-over effect. Further-
more, 6-month randomised controlled trials (RCTs)
using similar grade preparations have shown that CS
1200 mg/day plus glucosamine 1500 mg/day can provide
significant pain relief over placebo [9] and comparable
pain relief with celecoxib [10] in a subgroup of patients
with moderate-to-severe knee pain.
CS is a natural product extracted from animal cartilage
(e.g. bovine trachea). A recent Cochrane review concluded
that CS, alone or in combination with glucosamine, has a
beneficial effect on pain and joint space narrowing (JSN)
in patients with knee OA [11]. Of note, different sources
of CS with variable composition and purity have been
used in these studies, which may explain some heteroge-
neity of results [12]. RCTs using pharmaceutical-grade
preparations of CS have shown that at 800 mg/day the
treatment significantly reduced JSN as assessed using X-
ray imaging [13–15], and decreased cartilage volume lossas evaluated by magnetic resonance imaging (MRI) in a
pilot study [16]. In OA joint tissues, CS has been shown
to modify the chondrocyte death process, to improve the
anabolic/catabolic balance of the extracellular cartilage
matrix, to reduce some pro-inflammatory and catabolic
factors, and to reduce the resorptive properties of sub-
chondral bone osteoblasts [17–21]. These findings support
the mode of action of CS at reducing OA structural
change progression.
The aim of the current study was to ascertain whether
CS at 1200 mg/day, the maximum and most commonly
used therapeutic dosage of CS alone or in combination
with other drugs/agents such as glucosamine, over a
period of 24 months would reduce cartilage volume loss,
as assessed by MRI. Celecoxib was chosen as the compara-
tor for many reasons. First, it was shown in an RCT using
MRI that celecoxib and placebo have a non-different effect
on the progression of cartilage volume loss in knee OA
patients [22]. Moreover, celecoxib has an established
efficacy in knee OA treatment and widespread use [23].
It is preferred over other NSAIDs due to its lower inci-
dence of gastrointestinal side effects.
Methods
Study design
This 24-month randomised, double-blind, double-dummy
controlled study (ClinicalTrials.gov NCT01354145) of pa-
tients with symptomatic knee OA and clinical synovitis
aimed to explore the effect of CS and celecoxib on knee
OA cartilage volume loss. The study was performed in
Quebec, Canada. Patients were recruited by physicians in
four private clinics and one outpatient clinic (Service de
rhumatologie, Centre hospitalier universitaire de Sher-
brooke (CHUS), Sherbrooke, QC, Canada).
Patients
The study enrolled ambulatory men and women aged
40 years or older with primary symptomatic knee OA
whose condition justified symptomatic treatment, as de-
scribed previously [16]. They were diagnosed according
to the clinical and radiological criteria of the American
College of Rheumatology (ACR) [24], with clinical signs
of synovitis (warmth, swelling, or effusion), a disease
severity grade of 2–3 based on Kellgren–Lawrence
radiographic scoring [25], a minimal medial joint space
width of 2 mm on standing knee X-ray scan, and a visual
analogue scale (VAS) pain index of at least 40 mm while
walking. The X-ray inclusion criteria were selected not
only to comply with ACR recommendations but also to
avoid selection of patients with secondary OA and/or
with too severe disease such as knee varus/valgus
malalignment. Concomitant femoropatellar OA was not
quantified by X-ray imaging. Participants were required
to have no significant laboratory abnormalities. If both
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most pronounced symptoms was selected if within the
inclusion criteria. Full inclusion and exclusion criteria
are presented in Additional file 1: Table S1.
Treatments
Patients were assigned sequentially in a 1:1 ratio according
to a predefined randomisation scheme using a mathema-
tical algorithm and a randomisation list (Ropack Phar-
maceutical Packaging, Montreal, QC, Canada). The list
contained assignment of sequential numbers to one of the
two treatment groups, pharmaceutical-grade CS (Bioibérica
S.A., Barcelona, Spain) 1200 mg (three 400 mg capsules in
the morning) or celecoxib (Pfizer Canada, Saint-Laurent,
QC, Canada) 200 mg (one 200 mg capsule + two placebo
capsules in the morning) for 24 months. All products were
over-encapsulated to have the same appearance, size, and
colour. The patients, site personnel, and sponsor were
blinded to treatment.
Patients were not permitted to take other NSAIDs
during the study (or during the week before randomisa-
tion), but could take acetaminophen (up to 3 g/day) with
consumption interrupted 48 hours preceding evaluations.
The prior and concomitant treatment, blinding, treat-
ment compliance, and study schedule are described in
Additional file 1: Methods.
Outcomes
The primary endpoint was percentage of cartilage vol-
ume loss over time in the lateral compartment (condyle
and tibial plateau) of the target knee from baseline to
24 months. The decision for selecting this criterion was
based on the findings of the pilot study [16] and those of
other similar RCTs [26, 27]. The secondary endpoints
included changes in percentage of cartilage volume loss
in the medial compartment, synovitis severity (thickness
of the synovial membrane), bone marrow lesion (BML)
grade, and synovial fluid volume. The outcomes also
included assessment on the VAS of knee pain, Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) scores, quality of life (QoL) Short Form-36
General Health (SF-36) scores, clinical evaluation (swell-
ing, visual examination; effusion, bulge sign), analgesic
consumption, and AEs, which were recorded during
physical examinations at the baseline visit and follow-up
visits at months 3, 6, 9, 12, 18, and 24. Safety outcomes
included discontinuation of study treatment due to AEs,
and changes in various laboratory measures and vital
signs.
Knee MRI acquisitions
MRI was performed at baseline and at 12 and 24 months
on 1.5 T scanners (Siemens, Erlangen, Germany; General
Electric, Milwaukee, WI, USA) using a standard kneecoil. The sequence acquisitions were as described previ-
ously for the cartilage [28] and synovial membrane [29].
The cartilage volume was measured by two experienced
readers trained by musculoskeletal radiologists using the
computer program Cartiscope™ (ArthroLab, Montreal,
QC, Canada) as described previously [30, 31]. The readers
were blinded to treatment and to MRI examination time
points except for the baseline. The change in knee car-
tilage volume was obtained by subtracting the follow-
up volume from the initial (baseline) volume. The
reproducibility of the method has been demonstrated
previously to be excellent: root mean square (RMS)
coefficient of variation percentage (CV%) of 2.2 % for
the global cartilage volume, 1.6 % for the medial com-
partment, and 2.6 % for the lateral compartment [30]
and inter-reader and intra-reader intra-class correlation
(ICC) of 0.94–0.99 [32]. In addition, the reproducibility
of the reading is evaluated periodically using standard
operating procedures (SOP; ArthroLab). The data show
consistency of the method over time.
The extent of synovitis was assessed by measuring syn-
ovial thickness (mm) in four regions of interest (ROIs):
the medial and lateral articular recess and the medial
and lateral outer wall of the suprapatellar bursa [29].
The inter-reader and intra-reader correlation was excel-
lent with ICC of 0.82–0.91 [29] and consistency of the
method over time (SOP; ArthroLab). Of note, the meas-
urement of the synovial membrane thickness according
to this method relies on the presence of synovial fluid to
localise the membrane in the different ROIs. An absence
of synovial fluid, especially in the area of the medial
suprapatellar bursa, thus accounts for missing values.
The synovial fluid was determined using a fully auto-
mated system as described previously [33]. Validation ex-
periments revealed excellent coefficients of variation with
a calibrated cylinder (1.4 %), sphere phantoms (0.8 %),
manual quantification (r = 0.98, p < 0.0001), and compari-
son with direct aspiration (r = 0.88, p = 0.0008) [33].
BML were assessed in the same MRI sequences used
for the cartilage [34]. The extent of the BML was evaluated
in the global knee and each of the subregions using the
following scale: 0, absence; 1, <25 %; 2, 25–50 %, 3, >50 %
of the surface of the respective region regardless of the
presence of additional smaller lesions. Reliability of the
scoring system for BML changes was found to be excellent
with ICC ranging from 0.88 to 0.93 [34] and consistency
of the method over time (SOP; ArthroLab).
Statistical analysis
The study populations were carefully defined in the stat-
istical analysis plan (SAP). The safety population included
all randomised patients who received at least one dose
of study treatment (n = 194 at baseline). The modified
intention-to-treat (mITT) population comprised all






Female 53 (54.6) 61 (62.9)
Age (years) 61.4 ± 9.3 61.3 ± 8.5
Body mass index (kg/m2) 30.1 ± 5.8 32.3 ± 5.8
At least one previous medical condition 86 (88.7) 86 (88.7)
At least one active medical condition 96 (99.0) 97 (100.0)
Cartilage volume (mm3)
Lateral compartment 4613 ± 1755 4405 ± 1157
Condyle 2621 ± 1073 2476 ± 716
Plateau 1993 ± 799 1930 ± 540
Medial compartment 4515 ± 1537 4255 ± 1217
Condyle 2807 ± 971 2646 ± 779
Plateau 1708 ± 623 1609 ± 489
Synovial membrane thickness (mm) 1.0 ± 0.2 1.0 ± 0.2
BML score (global knee)a 2.6 ± 3.0 2.7 ± 2.5
Synovial fluid volume (ml) 13.8 ± 14.6 10.8 ± 10.9
Joint swelling and effusion
Swelling 76 (78.4) 78 (80.4)
Effusion 76 (78.4) 71 (73.2)
Both 59 (60.8) 55 (56.7)
Pain VAS (mm)a 62.42 ± 15.51 59.26 ± 18.10
WOMACa
Total score (0–240) 124.9 ± 38.1 126.7 ± 43.9
Pain score (0–50) 25.6 ± 8.1 25.5 ± 9.0
Stiffness score (0–20) 10.8 ± 3.7 11.7 ± 4.3
Physical function score (0–170) 88.5 ± 28.7 89.5 ± 32.5
Quality of life (SF-36)a
Physical component summary 35.4 ± 7.8 35.7 ± 8.1
Mental component summary 51.7 ± 9.5 52.7 ± 11.0
Data shown as number of patients (%) or mean ± standard deviation
aData were not available for two patients in the chondroitin sulfate group
BML bone marrow lesion, SF-36 Short Form-36, VAS visual analogue scale,
WOMAC Western Ontario and McMaster Universities Osteoarthritis Index
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study medication and for whom at least one post-
baseline efficacy MRI measurement was available. The
according-to-protocol (ATP) population included patients
who fully complied with the study’s 24-month proto-
col and for whom all MRI evaluations were available.
Data were entered into a computerised database using
a blinded double-entry procedure, after which descrip-
tive statistics for patient characteristics were tabulated.
Before locking the database, the following actions were
performed under conditions blinded for the type of
intervention: the database was cleaned, all queries were
resolved, a review meeting regarding blinded data was
conducted, protocol deviations were identified, the SAP
was developed, and signed approval was obtained. Fol-
lowing the final database lock, the statistical analysis
was performed by an independent expert biostatistics
firm (Inferential, Paris, France).
Descriptive variables at baseline are presented as
number (percentage) or mean ± standard deviation
(SD). Differences between the two treatment groups
were assessed using a Kruskal–Wallis test or Student’s t
test for quantitative variables, and a chi-squared test or
Fisher’s exact test for categorical variables. Analgesic
consumption was tallied and compared between the
two groups. The primary efficacy outcome measure for
structure modification was percentage cartilage volume
loss in the lateral compartment of the target knee after
24 months of enrolment for the mITT population who
had at least one post-baseline MRI measurement while
using, as specified in the SAP, the imputation method
of the last observation carried forward (mITT-LOCF).
Because of the difference at baseline in body mass
index (BMI) values between the two treatment groups
(Table 1), an analysis of covariance (ANCOVA) including
BMI as a covariate was performed on the mITT-LOCF
population. In order to provide an additional measure of
treatment efficacy, the ATP population (i.e. patients who
completed the study according to the 24-month protocol)
was also assessed using the ANCOVA method. Additionally,
the data from the mITT and ATP populations were also
analysed using a generalised linear mixed-model analysis.
Secondary efficacy analyses of structural changes were
done using the same methodology. Comparison of symp-
tom changes using the WOMAC questionnaire, VAS pain,
QoL SF-36, knee swelling and effusion, and safety were
assessed on all available data as specified in the SAP.
No sample size estimation was carried out because this
was an exploratory study. Statistical tests were two-sided
and significance reached at p < 0.05. No statistical ad-
justments were made for multiple comparisons while
analysing secondary outcomes. Statistical analyses
were performed using SAS® software version 9.3 (SAS
Institute, Cary, NC, USA).Results
Patients
The study was conducted from 21 June 2011 to 10
September 2014. A total of 194 patients were randomised
to CS or celecoxib. The study populations used for ana-
lyses are as described in Fig. 1.
No differences were found in the baseline characteristics
of the patient populations (Table 1) with the exception of
BMI; although values for both groups were in the obesity
category (≥30 kg/m2), a higher value was found in the
celecoxib group.
No significant difference between the treatment groups
was found for previous or concomitant medications
(Additional file 1: Table S2).
Fig. 1 Patient disposition. *Primary reasons for discontinuation. †mITT includes ATP patients plus those with MRI at 12 months but with MRI
missing at final visit. ATP according-to-protocol, mITT modified intention-to-treat, MRI magnetic resonance imaging
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Cartilage volume
In the adjusted mITT-LOCF analysis (n = 138), the per-
centage cartilage volume loss in the lateral compartment
(primary endpoint) was not different in the CS (n = 69)
and celecoxib (n = 69) groups at 24 months (Table 2). In
the medial compartment and medial condyle, the cartilage
volume loss was significantly less in the CS group at
24 months (p = 0.018 and p = 0.008, respectively) com-
pared with celecoxib. The results from the generalised lin-
ear mixed-model analysis at 24 months showed p = 0.038
for the medial compartment and p = 0.015 for the medial
condyle. However, the results of the adjusted analysis for
the ATP population (n = 120; Table 2) showed a significant
reduction in cartilage volume loss in CS-treated patients
at 12 months for the medial compartment (p = 0.049) and
at 24 months for the medial compartment and medial
condyle (p = 0.021 and p = 0.010, respectively). The results
from the generalised linear mixed-model analysis showed
p = 0.043 and p = 0.035 for the medial compartment at
12 months and 24 months, respectively, and p = 0.015 for
the medial condyle at 24 months.Synovial membrane
The assessment of the mean synovial thickness in the
global knee (four ROIs together) was not different
between treatment groups at baseline (Table 1). The
change in synovial membrane thickness between the two
therapeutic groups was not different at any time point in
both mITT (n = 138) and ATP (n = 120) population
analyses (Table 2). However, in post-hoc analysis, we also
examined the changes in synovial thickness in one of the
four ROIs, the medial suprapatellar bursa (n = 50;
Table 3). Because such measurement is reliant on the
presence of synovial fluid to localise the membrane, the
absence of synovial fluid accounts for missing values.
Data showed, in patients for whom the assessment of
thickness was possible at baseline and at 24 months, a
numerical trend (p = 0.076) towards a decrease at
24 months in the CS group versus the celecoxib group.
This is associated with a significant decrease (p = 0.045)
in the cartilage volume loss in the medial compartment.
Moreover, when analysed based on whether patients had
experienced a decrease or increase in synovial mem-
brane thickness from baseline to 24 months (Table 3),
Table 2 Changes in MRI parameters
mITT-LOCF population 24 months
Chondroitin sulfate Celecoxib p valuea
(n = 69) (n = 69)
Cartilage volume loss (%)
Lateral compartment –4.1 ± 3.1 –4.4 ± 3.0 0.814
Condyle –3.0 ± 3.1 –4.1 ± 3.7 0.144
Plateau –5.8 ± 4.7 –4.8 ± 3.5 0.182
Medial compartment –6.3 ± 3.2 –8.1 ± 4.2 0.018
Condyle –5.5 ± 3.9 –7.7 ± 4.7 0.008
Plateau –7.6 ± 4.0 –8.6 ± 4.8 0.276
Synovial membrane thicknessb (mm) 0.13 ± 0.25 0.14 ± 0.24 0.948
Synovial fluid volume (ml) –2.6 ± 14.5 –2.0 ± 11.8 0.776
BML scoreb 1.1 ± 1.7 0.8 ± 1.7 0.322
ATP population 12 months 24 months
Chondroitin sulfate Celecoxib p valuea Chondroitin sulfate Celecoxib p valuea
(n = 57)c (n = 63) (n = 57)c (n = 63)
Cartilage volume loss (%)
Lateral compartment –3.4 ± 2.7 –3.3 ± 2.5 0.932 –4.6 ± 3.0 –4.4 ± 2.8 0.753
Condyle –2.5 ± 3.2 –3.0 ± 3.0 0.234 –3.4 ± 3.0 –4.2 ± 3.6 0.316
Plateau –4.6 ± 3.5 –3.8 ± 3.1 0.194 –6.3 ± 4.6 –4.8 ± 3.5 0.081
Medial compartment –4.5 ± 2.6 –5.6 ± 3.0 0.049 –6.6 ± 3.3 –8.4 ± 4.2 0.021
Condyle –3.8 ± 3.2 –5.0 ± 3.8 0.100 –5.7 ± 4.0 –8.1 ± 4.7 0.010
Plateau –5.5 ± 3.0 –6.6 ± 3.8 0.155 –8.0 ± 4.2 –9.0 ± 4.8 0.334
Synovial membrane thicknessb (mm) 0.03 ± 0.18 0.06 ± 0.18 0.579 0.15 ± 0.26 0.15 ± 0.24 0.731
Synovial fluid volume (ml) –5.5 ± 12.6 –1.8 ± 9.2 0.326 –3.9 ± 15.4 –2.1 ± 12.2 0.945
BML scoreb 0.7 ± 1.4 0.3 ± 1.2 0.051 1.1 ± 1.7 0.8 ± 1.7 0.322
Data are mean ± standard deviation
aAnalysis of covariance; model includes BMI as covariate; bold indicates statistical significance
bGlobal knee
cAmong the 58 patients in the chondroitin sulfate group who completed the study, one patient did not complete the MRI at 24 months
ATP according-to-protocol, BMI body mass index, BML bone marrow lesion, LOCF last observation carried forward, mITT modified intention-to-treat, MRI magnetic
resonance imaging





















–0.66 ± 22.72 +17.96 ± 33.73 0.076 –0.23 ± 0.27 –0.14 ± 0.21 0.446 +0.13 ± 0.09 +0.25 ± 0.17 0.030
Medial compartment
Cartilage volume loss (%) –6.8 ± 3.5 –9.4 ± 4.7 0.045 –7.5 ± 3.7 –11.3 ± 3.5 0.036 –6.4 ± 3.4 –7.8 ± 4.8 0.404
Data are mean ± standard deviation
aData from patients who presented a decrease or an increase in synovial membrane thickness at 24 months
bSynovial membrane thickness measurement is reliant on the presence of synovial fluid to localise the membrane; absence of synovial fluid accounts for missing values
cStudent’s t test or Wilcoxon Mann–Whitney test, bold indicates statistical significance
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cantly lesser increase (p = 0.030) in synovial membrane
thickness compared with those in the celecoxib group.
The patients in the CS group who experienced a de-
crease in synovial membrane thickness had significantly
less cartilage volume loss (p = 0.036) than those in the
celecoxib group.
Synovial fluid volume and BML score
Analyses showed no significant differences between the
two treatment groups in baseline values (randomised
patients, n = 194; Table 1) or in the changes (mITT, n =
138; ATP, n = 120; Table 2) in synovial fluid volume.
For BML, the only significance was found in the changes
at 12 months (p = 0.051) in the ATP population.
Joint effusion/swelling
The incidence of joint effusion and/or swelling de-
creased similarly in both groups during the study in
the randomised patient population (all available data,
baseline, n = 194; Additional file 1: Figure S1). A
marked reduction in the incidence (%) of patients
with joint swelling plus effusion was observed in both
CS and celecoxib groups (42 % and 29 %, respectively)
at 24 months.
Symptoms and function
Both therapeutic groups experienced a reduction in
disease symptoms over time (all available data; baseline
n = 194) (Fig. 2). The decrease in WOMAC scores
(Fig. 2a–d) was slightly more pronounced in the cele-
coxib group compared with the CS group, mostly at
earlier time points (months 3 and 6), but statistical sig-
nificance was never reached except for the WOMAC
total at month 3 (Fig. 2a) and stiffness at months 3 and
6 (Fig. 2c). At 24 months, the reduction in WOMAC
pain (Fig. 2b) was 36 % for the CS group and 42 % for
the celecoxib group. The level of pain on VAS decreased
over time in both treatment groups (Fig. 2e). The re-
duction at 24 months was 38 % and 43 % for the CS
and celecoxib groups, respectively (Fig. 2e).
With regards to the QoL SF-36 physical and mental
component scores, an improvement in QoL was found
for both groups without significant differences between
them (data not shown).
The overall daily consumption of rescue analgesic
(acetaminophen) was not different between the CS and
celecoxib groups (584 versus 472 mg/day).
Safety
Study durations (mean ± SD) were 581 ± 254 and 579 ±
262 days in the CS and celecoxib groups, respectively
(n = 194), and treatment durations were 543 ± 260 and
564 ± 263 days, respectively.A total of 78 patients (80.4 %) in the CS group and 79
patients (81.4 %) in the celecoxib group reported at least
one AE during the study. The most frequent AEs
(Table 4) at the system organ class (SOC) level were
musculoskeletal and connective tissue disorders, infec-
tions and infestations, and gastrointestinal disorders.
The most common AEs by preferred term were naso-
pharyngitis, arthralgia, dyspepsia, headache, and back
pain. Significant differences between the two groups
were seen only for back pain and skin and subcutaneous
tissue disorders (Table 4). The vascular disorders de-
scribed in the table were hypertension (CS, n = 4; cele-
coxib, n = 3) and hot flush (CS, n = 1). Most emergent
AEs were mild to moderate with no significant differ-
ence between treatment groups (Table 5). The overall
frequency of patients with emergent AEs considered
possibly or probably related to study treatment, including
cardiovascular events (mainly hypertension; CS, n = 4,
celecoxib, n = 4), was similar in the two groups. Findings
regarding the AEs leading to study withdrawal were also
similar in the two therapeutic groups. No death occurred
during the study. Ten patients in the CS group versus
six in the celecoxib group experienced at least one ser-
ious adverse event (SAE). One SAE (iron-deficiency an-
aemia) was considered by the investigator to be related
to treatment in one patient in the CS group and two
SAEs (pneumonia and pulmonary embolism) in one pa-
tient in the celecoxib group.
Discussion
In this 24-month RCT, although we found no statisti-
cally significant reduction in cartilage volume loss by CS
treatment in the lateral compartment, which was the
primary outcome of the study, CS at 1200 mg/day was
found to have a beneficial effect versus celecoxib
200 mg/day on cartilage volume loss in the medial
compartment in knee OA patients. Moreover, CS, to a
greater extent than celecoxib, induced a lesser increase
in synovial thickness in the medial suprapatellar bursa
that was associated with a decrease in cartilage volume
loss in the medial compartment. There was also no evi-
dence of superiority of one treatment over the other at
improving disease symptoms except joint stiffness in
the early phase of the study, which was greater in cele-
coxib patients. These findings provide new information
about the potential benefit of long-term treatment with
CS in knee OA patients.
The reduction in cartilage volume loss found with CS
in the current study is in line with several other RCTs
[13–16] and meta-analyses and reviews [11, 35–38], in
which MRI (cartilage volume) or X-ray imaging (JSN)
were used to assess disease progression, a number of
which used a placebo as a comparator [13–15], including





Fig. 2 Change in symptoms and function from baseline based on
available data. WOMAC (a) total, (b) pain, (c) stiffness, and (d)
function subscales, and (e) VAS, by visit. Data are mean of the
relative change (%) from baseline. Statistical analyses comparing
chondroitin sulfate and celecoxib were performed using Student’s t
test or the Kruskal–Wallis test. CS chondroitin sulfate, CX celecoxib,
WOMAC, Western Ontario and McMaster Universities Osteoarthritis
Index, VAS visual analogue scale
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cant reduction in cartilage volume loss with CS plus
glucosamine, but not with CS alone, compared with
patients treated with placebo. The results of the latter
[39], which used X-ray imaging and JSN to assess the
disease-modifying osteoarthritis drug (DMOAD) effect,
could possibly be explained by the fact that it was under-
powered and of too short a duration for such imaging
technology to allow an accurate assessment of possible
changes related to treatment. Some other meta-analyses
[40–42] have reported no beneficial effect of CS on JSN.
Such findings can be at least partly explained by the het-
erogeneity between results of the studies included in the
analyses, which may have been related, to some extent,
to the use of non-pharmaceutical-grade CS as the thera-
peutic agent in some trials [12, 43, 44].
The change in cartilage volume in the lateral compart-
ment was chosen as the primary endpoint based mainly
on the results of the pilot study which reported signifi-
cantly less cartilage volume loss in the lateral compart-
ment with CS versus placebo [16], as well as two other
knee OA RCTs using MRI [26, 27]. Here, the protective
effect was found only in the medial compartment. This
discrepancy could probably be explained by many factors
including the difference in disease severity between the
patients in each study. Patients in the current study had
less severe disease than those in the pilot study [16], as
evidenced by higher knee cartilage volume, particularly
in the medial compartment. Because knee OA structural
damage (cartilage volume loss) in such patients is pre-
dominantly seen in the medial compartment, disease
progression in the lateral compartment may not have
been sufficient for CS to demonstrate a significant thera-
peutic effect, as shown in a recent report [45]. Moreover,
the duration of treatment in the pilot study of only
12 months and a lower dosage of CS (800 mg/day) may
have precluded the finding of a positive effect in the
medial compartment. Nevertheless, we believe that the
present findings are of great importance from many as-
pects. First, they are very clinically relevant, as a recent
consensus of experts recommends cartilage volume loss
in the medial compartment as a clinical trial outcome
[46]. The experts agree that it can predict knee replace-
ment, is sensitive to change, and predicts outcome in a
continuous manner. This is quite interesting in the






Events n (%) Events n (%)
Musculoskeletal and connective tissue disorders 72 37 (38.1) 59 38 (39.2) >0.999
Arthralgia 19 14 (14.4) 14 11 (11.3) 0.669
Back pain 17 16 (16.5) 5 5 (5.2) 0.019
Pain in extremity 6 3 (3.1) 8 7 (7.2) 0.331
Infections and infestations 66 34 (35.1) 61 32 (33.0) 0.880
Nasopharyngitis 28 19 (19.6) 18 15 (15.5) 0.572
Gastrointestinal disorders 37 27 (27.8) 44 29 (29.9) 0.874
Dyspepsia 12 12 (12.4) 12 12 (12.4) 1.000
Gastroesophageal reflux disease 5 5 (5.2) 5 5 (5.2) 1.000
Nervous system disorders 21 16 (16.5) 22 21 (21.6) 0.465
Headache 15 12 (12.4) 10 10 (10.3) 0.821
Respiratory, thoracic, and mediastinal disorders 19 15 (15.5) 20 14 (14.4) >0.999
Sinusitis 5 5 (5.2) 6 6 (6.2) >0.999
Injury, poisoning, and procedural complications 18 14 (14.4) 18 13 (13.4) >0.999
General disorders and administration site conditions 12 11 (11.3) 12 11 (11.3) 1.000
Skin and subcutaneous tissue disorders 3 3 (3.1) 11 11 (11.3) 0.049
Psychiatric disorders 4 4 (4.1) 9 9 (9.3) 0.250
Investigations 6 6 (6.2) 6 6 (6.2) 1.000
Surgical and medical procedures 8 5 (5.2) 8 6 (6.2) >0.999
Vascular disordersb 7 6 (6.2) 5 4 (4.1) 0.747
Data shown are number of events or patients (%)
aChi-squared test or Fisher’s exact test for proportions (%), bold indicates statistical significance
bVascular disorders include mainly hypertension, varicose veins, and ulcers






Events n (%) Events n (%)
At least one AE 305 78 (80.4) 299 77 (79.4) >0.999
Intensity
Mild 203 61 (62.9) 215 61 (62.9) 1.000
Moderate 89 47 (48.5) 68 41 (42.3) 0.471
Severe 13 9 (9.3) 16 10 (10.3) >0.999
SAE 16 10 (10.3) 9 6 (6.2) 0.435
Relationship to study treatment
Not related 246 67 (69.1) 241 68 (70.1) >0.999
Uncertain 20 14 (14.4) 23 13 (13.4) >0.999
Relatedb 39 27 (27.8) 35 24 (24.7) 0.745
AE that led to study withdrawal 13 13 (13.4) 12 11 (11.3) 0.828
Ongoingc 95 50 (51.5) 100 50 (51.5) 1.000
aChi-squared test for proportions (%)
bRelationship considered possible, probable, or very probable
cNot resolved/recovered at the end of the study
AE adverse event, SAE severe adverse event
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reported previously to have a beneficial effect on the need
for total knee replacement in a 4-year follow-up study
in knee OA [47]. A significant number of the patients
(n = 134) who were randomised in the study are now
being followed for a period of 4 years after study comple-
tion to evaluate the cumulative incidence of total knee
replacement to ascertain whether the finding of our
previous study [47] of the sparing effect of CS treatment
on knee replacement could be confirmed. The results of
the present study are also most helpful with regard to the
selection of primary endpoints in future DMOAD RCTs.
The selection of a very specific region of the knee in OA
trials may not be the most optimal approach, as demon-
strated in this study and in another recent RCT report
[26]. This obviously needs to be examined more closely as
results from additional RCTs become available.
The finding of a reduction in synovitis in the medial
compartment by CS treatment in certain patients is in-
teresting. It provides a hypothesis about the mechanism
by which the effect of CS on cartilage volume loss is
mediated. It also supports the findings of the pilot study
regarding the effect of CS on synovitis [16].
The finding that CS had a beneficial effect comparable
with that of celecoxib on pain, stiffness, physical func-
tion, and QoL is in line with a recent randomised trial
in which CS in combination with glucosamine provided
non-inferior pain relief to celecoxib [10] and supports
findings from previous trials [13, 15, 48] and meta-
analyses [11, 42, 49] that have also reported a signifi-
cant beneficial effect of CS (with or without glucosa-
mine) on pain. Of note is that not all clinical studies
with CS have shown a significant effect on pain [14, 39],
while others found a significant effect only in patients with
moderate to severe pain [9]. Differences among the pa-
tient populations, product formulations that were studied,
and follow-up times between studies may explain, to some
extent, those discrepancies.
Regarding safety, this study confirmed the good toler-
ability of both treatments for up to 24 months, with no
new safety issue, including cardiovascular events, arising
for either treatment. These findings are similar to those
observed in the MOVES study [10], which compared the
symptomatic efficacy of CS plus glucosamine hydro-
chloride versus celecoxib in knee OA patients. It should,
however, be taken into consideration that the patients
included in this study and in the MOVES study [10] were
those with low-risk cardiovascular and gastrointestinal
diseases, which could have impacted the safety results.
As with all studies, the present study has some limita-
tions. The relatively small sample size of this exploratory
study and less severe disease severity in the patient
population may have contributed to an underestimation
of the effects of CS in the lateral compartment. Althoughpatients with knee malalignment were excluded, such
angulation was not assessed per se as an outcome variable
and may be associated with the knee compartment in
which cartilage volume loss could progress despite ther-
apy. Additionally, although there is a well-known placebo
effect in OA [50], we did not include a placebo group
because it was felt that this would have been unethical,
particularly in a 24-month study, and CS has already
been shown to have a beneficial effect on JSN and/or
pain in a number of placebo-controlled studies in knee
OA [13–16, 48]. Similarly, celecoxib has proven pain
efficacy over placebo in OA in several studies [51–53].
Moreover, celecoxib was found to have a neutral effect
similar to placebo on cartilage volume loss in knee OA
patients [16]. The interruption period for acetamino-
phen before evaluations was sufficient to have no effect
on the studied pain outcomes.
Conclusion
This trial demonstrated, for the first time in a 24-month
RCT using MRI, the superiority of CS over celecoxib at
reducing the long-term progression of knee OA cartilage
volume loss. Moreover, both drugs were found effective
at reducing the symptoms of OA over the entire duration
of the 24-month study, with no superiority of one over the
other. These findings are interesting with regard to the
potential usefulness of CS for long-term management of
knee OA. A definitive study, however, will be required if
one wishes to fully confirm the findings.
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